Investigation of cerebrovascular reactivity in post-COVID-19 syndrome using functional magnetic resonance imaging

niversitätsklinikum Tübingen0 sites90 target enrollmentDecember 4, 2023

Overview

No summary available.

Registry

who.int

Start Date

December 4, 2023

End Date

TBD

Last Updated

last year

Study Type

Observational

Sex

All

Sponsor

niversitätsklinikum Tübingen

•Willingness to provide the written informed consent and the ability to give consent.
•\-SARS\-CoV\-2 infection confirmed by PCR test at least 12 weeks ago and the presence of a clinical neurological post\-COVID syndrome (depending on the subgroup, leading symptom complex fatigue/concentration and memory disorder/headache/dizziness or leading symptom complex myopathy/neuropathy).
•\-Inclusion criterion for the control group after SARS\-CoV\-2 infection without post\-COVID syndrome is a SARS\-CoV\-2 infection at least 12 weeks ago, confirmed by PCR test.

•\-Contraindications against MRI examinations; if metallic foreign bodies are present, it is checked before the examination whether the materials used are MRI\-compatible and the examination can take place without increased risk
•\- Persons with known ischemic infarcts, as well as known hemodynamically relevant extra\- and intracranial and vascular diseases
•\- Persons with known neurological or psychiatric illnesses prior to infection with SARS\-CoV\-2
•\- Persons with illnesses that prevent them from lying quietly in the examination device for 60 minutes (e.g. pain, claustrophobia, limited temperature sensitivity and/or increased sensitivity to body heating)
•\- Persons who do not appear to be cognitively or cardiopulmonarily capable of taking short breaths lasting 9 seconds
•\- Persons whose pregnancy has not been ruled out with certainty
•\- In the subgroup consisting of persons without post\-COVID syndrome any of the following symptoms:
•o Muscle weakness/muscle pain
•o Anxiety/depression
•o Memory/concentration disorders